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NOTES AND COMMENTS
Impact of treatment of Helicobacter pylori on the normal gastro-
intestinal microflora
Helicobacter pylori is known to be associated with chronic
gastritis, peptic ulcer disease and gastric cancer. Eradication of
Helicobacter pylori is recognized internationally to be the first-
line treatment, and the treatment regimens for this infection
have varied. The use of an acid suppressive agent together with
one or two antimicrobial agents has been proposed [1]. Triple
therapies containing proton pump inhibitors in combination
with two of amoxycillin, clarithromycin or metronidazole are
the most widely recommended regimens used in Europe today
[2,3]. Exposure to antimicrobial agents and acid suppressive
agents may disturb the ecological balance of the normal gastro-
intestinal microflora. This may lead to decreased colonization
resistance, with suppression of susceptible bacteria, and the
emergence of resistant strains [4,5]. Two clinical studies have
been performed at the Center of Gastroenterology, Huddinge
University Hospital, Stockholm, Sweden in order to compare
different treatment regimens with regard to ecological dis-
turbances in the normal oral, gastric and intestinal microflora
[6,7]. In the first study [6], 28 patients were included; 14 patients
were given 20 mg omeprazole capsules plus placebo capsules
twice daily for 10 days (OP), and 14 were given 20-mg ome-
prazole capsules plus 1000-mg amoxycillin capsules twice daily
for 10 days (OA). Half of the patients in each group had peptic
ulcer disease and half had dyspepsia with no active ulceration.
In the second study [7], 30 dyspeptic patients with Helicobacter
pylori infection were included. Fourteen patients were treated
with 20 mg omeprazole, 1000-mg amoxycillin tablets and 400-
mg metronidazole tablets twice daily for 7 days (OAM), and
16 patients were treated with 20 mg omeprazole, 250-mg cla-
rithromycin tablets and 400-mg metronidazole tablets twice
daily for 7 days (OCM). Inclusion criteria were Helicobacter
pylori infection confirmed by a positive rapid urease test (CLO),
age over 18 years and no intake of omeprazole, antacids or
antimicrobial agent 1 month prior to the study. The patients
were randomized, using double-blind selection. Both clinical
studies were approved by the local Ethics Committee at Hud-
dinge University Hospital, Karolinska Institute, Stockholm,
Sweden.
Several microorganisms were affected by the treatment regi-
mens. In saliva, no alterations other than an increase in the
number of Streptococcus intermedius bacteria were noticed in the
OP group. In the OA group, significant alterations were seen
during and after treatment. The number of viridans streptococci
increased and the number of Haemophilus spp. decreased. Two
patients became colonized by enterobacteria. The anaerobic
microflora was significantly reduced during treatment. The
microflora was, however, normal by day 35. When metron-
idazole was added to the regimen (OAM), similar alterations as
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in the OA group were seen, with additional significantly
increased numbers of yeasts. In the OCM group, the alterations
seen in the oral microflora were similar to those seen in the
OAM group.
In the gastric mucosa the microflora was evaluated from two
locations of the stomach, antrum and corpus. There was a
tendency for greater disturbances in the corpus than in the
antrum of the stomach. A general increase in the number
of gastric microorganisms was noticed during therapy in all
treatment groups. There was an inverse relationship between
the number of Helicobacter pylori bacteria and the normal micro-
flora, which was most pronounced in the group treated with
omeprazole alone (OP). Almost all bacterial groups increased
in numbers, but returned to pretreatment levels after treatment.
However, yeasts were present 4 weeks after treatment in both
the OP and the OA groups. Fewer alterations were seen in the
two triple therapy groups, OAM and OCM. A decrease in the
number of Bacteroides was seen 4 weeks after the end of treat-
ment in the OCM group.
A moderate increase in the number of microorganisms was
noticed in the intestinal microflora in the OP group. In the OA
group, overgrowth of resistant enterobacteria was observed.
Yeasts were not detectable on day 0, but were present in five
patients during treatment. In the OAM group, a significant
increase during treatment was seen in the numbers of entero-
cocci, enterobacteria and peptostreptococci. The number of
patients colonized with yeasts increased from zero to nine dur-
ing treatment; two patients harbored yeasts after treatment.
Anaerobic bacteria such as bifidobacteria and Clostridium spp.
were significantly suppressed during treatment. All alterations
in the OAM group were normalized 4 weeks after treatment.
In the OCM group, the numbers of anaerobic microorganisms
were significantly decreased both during and 4 weeks after
treatment.
In the OA group, a significant increase in the MIC values
was seen for intestinal Escherichia coli strains (P  0.05) during
treatment, and for enterobacteria other than Escherichia coli
strains from day 0 to day 10 (P  0.01), which persisted until
day 42 (P  0.05) (Mann–Whitney U-test). In the OAM
group, the MICs of amoxycillin were determined by the agar
dilution method for 741 strains collected from the saliva, the
gastric mucosa and feces. A significant increase in the MICs for
salivary isolates of Streptococcus spp. was seen on day 7
(P  0.001). The increase remained significant until day 35.
However, none of the streptococcal isolates was classified as
resistant to amoxycillin according to NCCLS criteria
(R  8 mg/L) [8]. Streptococcus spp. isolated from the gastric
mucosa showed increased MICs during (P  0.001) and after
(P  0.05) treatment. The MICs for Staphylococcus spp.
increased significantly (P  0.05) in the OAM group during
treatment, and the ratio of resistant strains, according to NCCLS
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criteria, increased from 30% to 64% during treatment
(R  0.5 mg/L). In feces, Enterococcus spp. showed a significant
increase (P  0.001) in MICs during treatment, which
remained high 4 weeks after treatment. The MICs for Entero-
bacteriaceae in feces increased significantly during treatment
(P  0.001), and the ratio of resistant strains, according to
NCCLS criteria (R  32 mg/L), increased from 12% to 76%
during treatment but decreased to 38% 4 weeks after treatment.
No significant alterations were seen in MICs among intestinal
Bacteroides spp., which were resistant to amoxycillin throughout
the study period [9]. All Helicobacter pylori strains were sus-
ceptible (MIC  0.016 mg/L) to amoxycillin.
In the OCM group, the susceptibility to clarithromycin was
tested for 742 strains isolated from saliva, gastric mucosa and
feces. Among the saliva and gastric mucosal isolates, a significant
increase in the MICs was seen on days 7 and 35 against Strep-
tococcus spp. (P  0.001). There was a significant shift, according
to the chi-square test, from susceptible streptococci on day 0
(resistant proportion was 5%), to resistant strains on day 7 (74%)
according to NCCLS criteria (R  1 mg/L) [8]. Twenty-six
percent of the saliva streptococci were still resistant on day 35.
In feces, Enterococcus spp. showed a significant increase
(P  0.001) in MIC values during treatment, but these returned
almost to pretreatment levels on day 35. The frequency of
clarithromycin-resistant Enterococcus spp. increased from 2% on
day 0 to 92% during treatment and was still 29% after treatment
(R  8 mg/L). The MICs for Enterobacteriaceae isolated in
feces increased significantly during treatment (P  0.001). The
MICs for Bacteroides spp. in feces increased significantly from
day 0 in the OCM group during and after treatment
(P  0.001). The frequency of resistant Bacteroides isolates
increased from 2% pretreatment to 76% and 59% on days 7 and
35, respectively (R  8 mg/L) [9]. All Helicobacter pylori isolates
were susceptible (MIC  0.016 mg/L) to clarithromycin
throughout the study period.
No significant alterations in the MICs of metronidazole
against Bacteroides spp. were noticed in either of the treatment
groups (OAM/OCM). Five of 20 tested Helicobacter pylori strains
from the OP and OA groups showed metronidazole resistance
((32 mg/L). No differences were seen between the different
sampling occasions. In the OAM/OCM groups, the MIC50
was 3 mg/L and the MIC90 was 32 mg/L, with no significant
differences between sampling occasions or the two treatment
groups.
A stable microflora in the oral cavity as well as in the gastro-
intestinal tract is of great importance to the host. The normal
microflora is challenged by the use of antimicrobial agents.
Quantitative alterations such as differences in the numbers of
different species in the microflora may reduce colonization
resistance, which in turn can lead to opportunistic infections
by exogenic and endogenic microorganisms such as C. difficile
and yeasts. Qualitative disturbances such as emergence of resist-
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ance in the microflora is also a worrisome aspect of antimicrobial
usage. Both the qualitative and quantitative effects were present
in all the tested anti-Helicobacter pylori treatment regimens. The
large ecological alterations seen in the oral microflora during
treatment imply a decreased colonization resistance. The micro-
flora of the gastric mucosa of the stomach was altered in all four
treatment groups. Different theories may be proposed to explain
the inverse relationship between the total numbers of micro-
organisms (other than Helicobacter pylori) and the numbers of
Helicobacter pylori. It may be due to the colonization resistance
expressed by the normal gastric microflora, differences in sus-
ceptibility to pH changes, or to a specific antimicrobial effect
of omeprazole against Helicobacter pylori [10,11]. The increase in
the numbers of gastric microorganisms was most pronounced
in the OP group, which indicates that the antibiotics used had
a suppressive effect on the microflora. Quantitative alterations
in the intestinal microflora were noticed in all groups, and were
most pronounced in the patients treated with triple therapy
(OAM, OCM). The total anaerobic microflora was strongly
suppressed in both treatment groups, mainly due to the effect of
metronidazole. The effect was most pronounced in the OCM
group, which is in accordance with a previous study, where
oral administration of clarithromycin to healthy volunteers was
shown to significantly suppress the anaerobic microflora [12].
The anaerobic intestinal microflora is considered to be respon-
sible for the colonization resistance in the intestinal tract and is
therefore of great importance. The proportion of cla-
rithromycin-resistant Bacteroides strains increased from 2% to
76% during treatment and was as high as 59% 4 weeks post-
treatment. This may be serious, since Bacteroides spp. are the
dominant species in the intestinal microflora, and are also mainly
responsible for serious anaerobic intra-abdominal infections
[13].
Over one half of the world’s population is considered to
be infected with Helicobacter pylori [14], and treatment of this
microorganism requires antimicrobial agents. Responsible
physicians must be aware of the ecological consequences for
the host.
In conclusion, treatment with antimicrobial agents aimed at
eradication of Helicobacter pylori has been shown to have negative
effects on the normal oral and gastrointestinal microflora, with
emergence of resistant strains and possibly even resistant Hel-
icobacter pylori as a consequence [15]. Anti-Helicobacter pylori
treatment should be prescribed only after a correctly identified
Helicobacter pylori infection. Although the treatment outcome
was better in the OCM group (100%) than in the OAM group
(71%), the amoxycillin-based treatment might be preferable
from an ecological point of view, since the qualitative alterations
in terms of emergence of resistant strains were more pro-
nounced and prolonged in the clarithromycin-based treatment
group. The threat of development and spread of antimicrobial-
resistant microorganisms requires an urgent effort to find new
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treatment strategies, preferably without antimicrobial agents,
such as a vaccine and improved prophylactic measures.
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